GoAI
Get started
iRhythm Technologies, Inc. logo

iRhythm Technologies, Inc.

IRTC

NASDAQHealthcareMedical - Devices

Open in GoAI

Latest quote

$128.51

+$0.54 · +0.42%

Aug 21, 3:55 PM ET

IRTC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

78

Undervalued

Momentum

34

Weakening

Sentiment

66

Bullish

Risk resilience

41

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Quentin S. Blackford
Listed since
Oct 20, 2016
Employees
2,400

Market position

Volume
451.64K
0.77× average
Average volume
588.51K
Average daily volume
Market cap
4.22B USD
Beta
1.32
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
6.17B USD
EV / EBITDA
-1,557.12×
Earnings yield
-0.78%
Free cash flow yield
0.61%

Profitability & efficiency

Return on equity
-29.17%
Return on assets
-4.37%
Return on invested capital
-4.16%

Financial health

Current ratio
4.63×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends81%40%-1%-42%Gross margin, FY2021: 66.16%Gross margin, FY2022: 68.54%Gross margin, FY2023: 67.35%Gross margin, FY2024: 68.86%Gross margin, FY2025: 70.57%Operating margin, FY2021: -30.96%Operating margin, FY2022: -27.69%Operating margin, FY2023: -25.40%Operating margin, FY2024: -19.52%Operating margin, FY2025: -4.93%Net margin, FY2021: -31.40%Net margin, FY2022: -28.27%Net margin, FY2023: -25.05%Net margin, FY2024: -19.14%Net margin, FY2025: -5.96%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 66.16%. Gross margin FY2022 68.54%. Gross margin FY2023 67.35%. Gross margin FY2024 68.86%. Gross margin FY2025 70.57%. Operating margin FY2021 -30.96%. Operating margin FY2022 -27.69%. Operating margin FY2023 -25.40%. Operating margin FY2024 -19.52%. Operating margin FY2025 -4.93%. Net margin FY2021 -31.40%. Net margin FY2022 -28.27%. Net margin FY2023 -25.05%. Net margin FY2024 -19.14%. Net margin FY2025 -5.96%.

Income trends

Revenue

747.14M USD+26.24%

Operating income

−36.81M USD+68.13%

Net income

−44.55M USD+60.67%
Income trends across reported periods834.37M USD485.45M USD136.53M USD−212.39M USDRevenue, FY2021: 322.83M USDRevenue, FY2022: 410.92M USDRevenue, FY2023: 492.68M USDRevenue, FY2024: 591.84M USDRevenue, FY2025: 747.14M USDOperating income, FY2021: −99.94M USDOperating income, FY2022: −113.78M USDOperating income, FY2023: −125.16M USDOperating income, FY2024: −115.51M USDOperating income, FY2025: −36.81M USDNet income, FY2021: −101.36M USDNet income, FY2022: −116.16M USDNet income, FY2023: −123.41M USDNet income, FY2024: −113.29M USDNet income, FY2025: −44.55M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 322.83M USD. Revenue FY2022 410.92M USD. Revenue FY2023 492.68M USD. Revenue FY2024 591.84M USD. Revenue FY2025 747.14M USD. Operating income FY2021 −99.94M USD. Operating income FY2022 −113.78M USD. Operating income FY2023 −125.16M USD. Operating income FY2024 −115.51M USD. Operating income FY2025 −36.81M USD. Net income FY2021 −101.36M USD. Net income FY2022 −116.16M USD. Net income FY2023 −123.41M USD. Net income FY2024 −113.29M USD. Net income FY2025 −44.55M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue747.14M USD591.84M USD492.68M USD410.92M USD322.83M USD
Cost of goods sold219.89M USD184.31M USD160.88M USD129.29M USD109.26M USD
Gross profit527.25M USD407.53M USD331.81M USD281.63M USD213.57M USD
Research and development84.61M USD103.83M USD60.24M USD46.61M USD38.67M USD
Selling, general, and administrative479.45M USD418.57M USD385.65M USD322.2M USD274.84M USD
Operating expenses564.06M USD523.04M USD456.97M USD395.42M USD313.51M USD
Interest income21.52M USD21.94M USD6.16M USD2.35M USD118K USD
Interest expense13.15M USD12.82M USD3.65M USD4.14M USD1.17M USD
Depreciation and amortization26.48M USD25.78M USD22.14M USD19.61M USD16.59M USD
Operating income−36.81M USD−115.51M USD−125.16M USD−113.78M USD−99.94M USD
Net income−44.55M USD−113.29M USD−123.41M USD−116.16M USD−101.36M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+69.42%
11 comparable reports
Latest EPS result
-0.01
Estimate -0.04 · Beat by 75.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.26-0.17-0.61-1.04Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 20, 2025: actual 0.01, estimate -0.29, surprise +103.45%, Beat. Q2 2025, reported May 1, 2025: actual -0.95, estimate -0.89, surprise -6.74%, Miss. Q3 2025, reported Jul 31, 2025: actual -0.44, estimate -0.53, surprise +16.98%, Beat. Q4 2025, reported Oct 30, 2025: actual -0.16, estimate -0.36, surprise +55.56%, Beat. Q1 2026, reported Feb 19, 2026: actual 0.17, estimate 0.02, surprise +750.00%, Beat. Q2 2026, reported Apr 30, 2026: actual -0.43, estimate -0.56, surprise +23.21%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.01, estimate -0.04, surprise +75.00%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 0.02, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates233.14M203.57M173.99M144.42MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 20, 2025: actual 164.33M USD, estimate 158.29M USD, surprise +3.81%, Beat. Q2 2025, reported May 1, 2025: actual 158.68M USD, estimate 153.39M USD, surprise +3.45%, Beat. Q3 2025, reported Jul 31, 2025: actual 186.69M USD, estimate 173.98M USD, surprise +7.30%, Beat. Q4 2025, reported Oct 30, 2025: actual 192.88M USD, estimate 184.77M USD, surprise +4.39%, Beat. Q1 2026, reported Feb 19, 2026: actual 208.89M USD, estimate 201.9M USD, surprise +3.46%, Beat. Q2 2026, reported Apr 30, 2026: actual 199.39M USD, estimate 194.11M USD, surprise +2.72%, Beat. Q3 2026, reported Aug 6, 2026: actual 224.17M USD, estimate 219.3M USD, surprise +2.22%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 222.45M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$174.88

36.07% upside
Past 12 months12-month forecastHigh $196Average $174.88Low $160

Rating distribution

20 ratings
Strong buy00%
Buy1785%
Hold315%
Sell00%
Strong sell00%

Recent analyst actions

12 institutions
B of A SecuritiesmaintainBuy

IRTC news

seekingalpha.com

iRhythm: The Algorithmic Margin Inflection Changes The Story

iRhythm Technologies is evolving from a cardiac patch producer to a comprehensive cardiac monitoring platform, leveraging software and workflow integration for a competitive advantage. Q2 2026 marked a financial…

Read source
gurufocus.com

Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, Aug.

Read source
prnewswire.com

Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket…

Read source
zacks.com

iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform

IRTC's VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.

Read source
zacks.com

Here's Why iRhythm Holdings, Inc. (IRTC) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read source
defenseworld.net

iRhythm Technologies $IRTC Shares Sold by Bank of America Corp DE

Bank of America Corp DE trimmed its holdings in iRhythm Technologies (NASDAQ: IRTC) by 41.7% in the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 432,539 shares of the company's…

Read source

IRTC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research IRTC

research.disclaimer